Natural Alternatives International, Inc. · NASDAQ:NAII
Natural Alternatives International — Investor Presentation (February 2026)
28 slides from Natural Alternatives International's investor presentation, February 2026
Slide 1: Investor Presentation February 2026
Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition. Natural Alternatives International, Inc. Investor Presentation February 2026 Nasdaq: NAII
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements reflect Natural Alternatives International, Inc.’s (the Company’s) current views about future events and financial performance b
Slide 3: Regulation G
Regulation G In addition, in order to assist you with period -over-period comparisons on a consistent and comparable basis, our presentation includes certain non-US GAAP information. This information excludes certain non-cash expenses, certain cash income and expense items related to our foreign cur
Slide 4: Company Snapshot
Company Snapshot NAII is the only pure-play public company that offers global formulation and manufacturing of customized nutritional supplements along with marketing branded and patented products Contract Manufacturing We provide private-label contract manufacturing services to companies that marke
Slide 5: Company Strengths
Company Strengths Multi-Continent Contract Manufacturing Facilities • Custom product formulation • State-of-the-art manufacturing facilities • Broad material acquisition & analysis • Certified in-house laboratory capabilities • Multiple packaging configuration capabilities In-House Brand Leveraging
Slide 6: Company Strengths
Company Strengths Growth Drivers From Organic Initiatives And Complementary Acquisitions • Expand existing customer products, base and channels • Expand in-house brands • Complementary acquisitions Solid Cash Flows And Strong Balance Sheet To Support Growth Objectives • TTM* net sales of $135.2 mill
Slide 7: Executive Management Team
Executive Management Team Mark A. LeDoux CEO and Chairman of the Board of Directors Mr. LeDoux founded Natural Alternatives International (NAI) in 1980. With over 45 years of experience since joining the nutritional supplements industry in 1975, Mr. LeDoux is considered a highly regarded leader and
Slide 8: Executive Management Team
Executive Management Team Kenneth E. Wolf President and Chief Operating Officer Mr. Wolf joined NAI in February 2008 as Chief Financial Officer, was promoted to Chief Operating Officer in June 2010 and has served as NAI’s President since October 2015. Mr. Wolf is responsible for design and implement
Slide 9: Overview – Capabilities
Overview – Capabilities Global Production • Up to 17 million capsules and 11 million tablets daily capacity • Up to 500,000 bottles finished product daily capacity • Highly sophisticated in-house laboratories Packaging • Warehousing – 7,400+ pallet capacity • HDPE/PP Bottles Regulatory • Full Label
Slide 10: Overview – Contract Manufacturing
Overview – Contract Manufacturing Product Formulation • Custom formulations • In-house science teams • Clinical study design and support • In-house product stability testing capabilities Material Acquisition and Analysis • Global raw material sourcing expertise • Transparency and tracking of materia
Slide 11: Overview – Patent & Trademark Licensing
Overview – Patent & Trademark Licensing In-house brand expansion leveraging our proprietary ingredients: CarnoSyn®, SR CarnoSyn® beta-alanine and TriBsyn . Sports Nutrition • Enhance athletic performance • Build muscle and reach peak sustainable performance • New sustained release form of CarnoSyn®
Slide 12: Worldwide Operations and Market Reach
Worldwide Operations and Market Reach NAI’s global footprint and scope facilitates greater opportunities and more dynamic client engagement Manno, Switzerland Carlsbad, CA Vista, CA NAI Offices and Operating Centers Primary Markets 12
Slide 13: Get To Know NAI
Get To Know NAI Welcome To NAI A personal welcome from founder & CEO Mark LeDoux Discover The NAI Difference The proven leader in custom formulation and contract manufacturing NAI Plant Tour Take an in-depth look at our new state-of-the-art manufacturing facility 13
Slide 14: Accreditations
Accreditations Industry leading accreditations and certification demonstrate our commitment to quality and are a strong barrier to entry Domestic (NAI) International (NAIE) Good Manufacturing Practices (cGMPs) (21 CFR 111) compliant – SwissMedic GMP certified – site registered and licensed FDA Inspe
Slide 15: Industry Trends
Industry Trends We will benefit from growing consumer interest in health and wellness 87% 66% 80% 87% - of consumers typically 66% - of consumers say 80% - of consumers who say use some type of vitamin, supplements are an supplements are an important mineral, or supplement1 important part of their p
Slide 16: US Supplement Market Forecast
US Supplement Market Forecast Supplement sales growth remains strong growing 4.4% to $64.4B in 2023; Supplement industry on track to approach $80B by 2027 and a CAGR of 5.2% between 2023 and 2027. SOURCE: Nutrition Business Journal: State of the Supplement Industry 2024 Inside the Bottle Summit 16
Slide 17: Financial Performance and Growth Objectives
Financial Performance and Growth Objectives 17
Slide 18: Historical Revenue and Adjusted EBITDA
Historical Revenue and Adjusted EBITDA Trailing twelve-month sales continue to rebound after FY24 saw key customers reduce purchases due to excess inventory levels in order to rebalance supply and demand after peak sales in FY22 as a result of the COVID-19 pandemic. These reductions were partially o
Slide 19: Historical Sales By Channel
Historical Sales By Channel $180 Millions $160 9% 6% $140 23% 6% 6% $120 41% 7% 26% 30% $100 18% $80 $60 68% 75% 68% 64% $40 53% $20 $- FY22 FY23 FY24 FY25 TTM** Direct Sales Retail Patent & Trademark Licensing ** Trailing 12 Months (TTM) – Includes January 2025 through December 2025 19
Slide 20: Acquisition Strategy
Acquisition Strategy Channels Verticals Health Care Practitioner Wellness Brands Multi-Level Marketer High Value Ingredient Suppliers Direct-to-Consumer Contract Manufacturers Specialty Retail Value-Add Distributors Drug Store Mass Markets Forms Vitamins, Minerals, Supplements Capsules/Tablets, Powd
Slide 21: Investment Thesis
Investment Thesis • Our available capacity increased by ~44% with the opening of our new high-volume powder facility in Q4 of FY23. Including this increase, our global capacity available for new business is ~75%. • New high-capacity blender came online January 2022 in our Vista, CA facility increasi
Slide 22: Investor Information
Investor Information Stock Symbol: NASDAQ: NAII Company website: http://www.nai-online.com Company Headquarters: 1535 Faraday Avenue Carlsbad, CA 92008 Investor Relations Contacts Michael Fortin Chief Financial Officer 760-736-7700 investor@nai-online.com 22
Slide 23: Appendix
Appendix Investor Relations Info 23
Slide 24: Historical Segment Performance
Historical Segment Performance Fiscal Year ended June 30, Trailing 12 2023 2024 2025 Months** Revenue Private Label Contract Manufacturing $ 145,294 $ 105,358 $ 121,779 $ 127,703 Patent & Trademark Licensing $ 8,721 $ 8,438 $ 8,081 7,454 Total Revenue $ 154,015 $ 113,796 $ 129,860 $ 135,157 Income (
Slide 25: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations In thousands, except per share data (Unaudited) (Unaudited) Three Months Ended Six Months Ended December 31, December 31, 2025 2024 2025 2024 NET SALES $ 34,795 100.0% $ 34,078 100.0% $ 72,525 100.0% $ 67,228 100.0% Cost of goods sold 32,304 92.8% 32,4
Slide 26: Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets In thousands (unaudited) December 31, June 30, 2025 2025 ASSETS Cash and cash equivalents $3,753 $12,325 Accounts receivable, net 17,763 14,644 Inventories, net 33,433 24,871 Other current assets 6,567 7,436 Total current assets 61,516 59,276 Property and equipm
Slide 27: Adjusted EBITDA Reconciliation (Non-US GAAP)
Adjusted EBITDA Reconciliation (Non-US GAAP) Natural Alternatives International, Inc. Adjusted EBITDA - Non-US GAAP Reconciliation (In Thousands) (Unaudited) Trailing 12 FY22 FY23 FY24 FY25 Months* Net Income (Loss) $10,712 $2,522 ($7,216) ($13,576) ($12,247) Interest Income - (33) (176) (168) (124)
Slide 28: Thank You
Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition. Thank You www.nai-online.com Nasdaq: NAII
Natural Alternatives International — Investor Presentation (February 2026) on 6ix